Gentamicin

Last updated

Gentamicin
Gentamicin C2.svg
Gentamicin.png
Clinical data
Pronunciation /ˌdʒɛntəˈmaɪsən/
Trade names Cidomycin, Genticyn, Garamycin, others
AHFS/Drugs.com Monograph
MedlinePlus a682275
License data
Pregnancy
category
Routes of
administration 		Intravenous, eye drop, Intramuscular injection, Topical administration, ear drop
Drug class Aminoglycoside antibiotic
ATC code
Legal status
Legal status
  • US: WARNING [2]
  • EU:Rx-only [3]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability limited bioavailability by mouth
Protein binding 0–10%
Elimination half-life 2 h
Excretion Kidney
Identifiers
  • (3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4,6-
    diamino-3-{[(2R,3R,6S)-
    3-amino-6-[(1R)-
    1-(methylamino)ethyl]oxan-2-yl]oxy}-
    2-hydroxycyclohexyl]oxy}-5-methyl-
    4-(methylamino)oxane-3,5-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.014.332 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C21H43N5O7
Molar mass 477.603 g·mol−1
3D model (JSmol)
  • O[C@]3(C)[C@H](NC)[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]1O[C@H](C(NC)C)CC[C@H]1N)[C@@H]2O)OC3
  • InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1 Yes check.svgY
  • Key:CEAZRRDELHUEMR-URQXQFDESA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Gentamicin is an aminoglycoside antibiotic used to treat several types of bacterial infections. [4] This may include bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis among others. [4] It is not effective for gonorrhea or chlamydia infections. [4] It can be given intravenously, by intramuscular injection, or topically. [4] Topical formulations may be used in burns or for infections of the outside of the eye. [5] It is often only used for two days until bacterial cultures determine what specific antibiotics the infection is sensitive to. [6] The dose required should be monitored by blood testing. [4]

Contents

Gentamicin can cause inner ear problems and kidney problems. [4] The inner ear problems can include problems with balance and hearing loss. [4] These problems may be permanent. [4] If used during pregnancy, it can cause harm to the developing fetus. [4] However, it appears to be safe for use during breastfeeding. [7] Gentamicin is a type of aminoglycoside [4] and works by disrupting the ability of the bacteria to make proteins, which typically kills the bacteria. [4]

Gentamicin is naturally produced by the bacterium Micromonospora purpurea , [8] [4] was patented in 1962, approved for medical use in 1964. [9] The antibiotic is collected from the culture of the Micromonospora by perforating the cell wall of the bacterium. Current research is underway to understand the biosynthesis of this antibiotic in an attempt to increase expression and force secretion of gentamicin for higher titer. Gentamicin is on the World Health Organization's List of Essential Medicines. [10] The World Health Organization classifies gentamicin as critically important for human medicine. [11] It is available as a generic medication. [12]

Medical uses

Gentamicin is active against a wide range of bacterial infections, mostly Gram-negative bacteria including Pseudomonas , Proteus , Escherichia coli , Klebsiella pneumoniae , Enterobacter aerogenes, Serratia , and the Gram-positive Staphylococcus . [13] Gentamicin is used in the treatment of respiratory tract infections, urinary tract infections, blood, bone and soft tissue infections of these susceptible bacteria. [14]

There is insufficient evidence to support gentamicin as the first line treatment of Neisseria gonorrhoeae infection. [15] Gentamicin is not used for Neisseria meningitidis or Legionella pneumophila bacterial infections (because of the risk of the person going into shock from lipid A endotoxin found in certain Gram-negative organisms). Gentamicin is also useful against Yersinia pestis (responsible for plague), its relatives, and Francisella tularensis (the organism responsible for tularemia often seen in hunters and trappers). [16]

Some Enterobacteriaceae , Pseudomonas spp., Enterococcus spp., Staphylococcus aureus and other Staphylococcus spp. have varying degrees of resistance to gentamicin. [17]

Special populations

Pregnancy and breastfeeding

Gentamicin is not recommended in pregnancy unless the benefits outweigh the risks for the mother. Gentamicin can cross the placenta and several reports of irreversible bilateral congenital deafness in children have been seen. Intramuscular injection of gentamicin in mothers can cause muscle weakness in the newborn. [14]

The safety and efficacy for gentamicin in nursing mothers has not been established. Detectable gentamicin levels are found in human breast milk and in nursing babies. [14]

Elderly

In the elderly, renal function should be assessed before beginning therapy as well as during treatment due to a decline in glomerular filtration rate. Gentamicin levels in the body can remain higher for a longer period of time in this population. Gentamicin should be used cautiously in persons with renal, auditory, vestibular, or neuromuscular dysfunction. [13]

Children

Gentamicin may not be appropriate to use in children, including babies. Studies have shown higher serum levels and a longer half-life in this population. [18] Kidney function should be checked periodically during therapy. Long-term effects of treatment can include hearing loss and balance problems. Hypocalcemia, hypokalemia, and muscle weakness have been reported when used by injection. [13]

Contraindications

Gentamicin should not be used if a person has a history of hypersensitivity, such as anaphylaxis, or other serious toxic reaction to gentamicin or any other aminoglycosides. [14] Greater care is required in people with myasthenia gravis and other neuromuscular disorders as there is a risk of worsening weakness. [4] Gentamicin should also be avoided when prescribing empirical antibiotics in the setting of possible infant botulism (Ampicillin with Gentamicin is commonly used as empiric therapy in infants) also due to worsening of neuromuscular function. [19]

Adverse effects

Adverse effects of gentamicin can range from less severe reactions, such as nausea and vomiting, to more severe reactions including: [13]

Nephrotoxicity and ototoxicity are thought to be dose related with higher doses causing greater chance of toxicity. [13] These two toxicities may have delayed presentation, sometimes not appearing until after completing treatment. [13]

Kidney damage

Kidney damage is a problem in 10–25% of people who receive aminoglycosides, and gentamicin is one of the most nephrotoxic drugs of this class. [20] Oftentimes, acute nephrotoxicity is reversible, but it may be fatal. [13] The risk of nephrotoxicity can be affected by the dose, frequency, duration of therapy, and concurrent use of certain medications, such as NSAIDs, diuretics, cisplatin, ciclosporin, cephalosporins, amphotericin, iodide contrast media, and vancomycin. [20]

Factors that increase risk of nephrotoxicity include: [20]

Kidney dysfunction is monitored by measuring creatinine in the blood, electrolyte levels, urine output, presence of protein in the urine, and concentrations of other chemicals, such as urea, in the blood. [20]

Inner ear

About 11% of the population who receives aminoglycosides experience damage to their inner ear. [21] The common symptoms of inner ear damage include tinnitus, hearing loss, vertigo, trouble with coordination, and dizziness. [22] Chronic use of gentamicin can affect two areas of the ears. First, damage of the inner ear hair cells can result in irreversible hearing loss. Second, damage to the inner ear vestibular apparatus can lead to balance problems. [22] To reduce the risk of ototoxicity during treatment, it is recommended to stay hydrated. [13]

Factors that increase the risk of inner ear damage include: [13] [14]

Pharmacology

Mechanism of action

Gentamicin is a bactericidal antibiotic that works by binding the 30S subunit of the bacterial ribosome, negatively impacting protein synthesis. The primary mechanism of action is generally accepted to work through ablating the ability of the ribosome to discriminate on proper transfer RNA and messenger RNA interactions. [23] Typically, if an incorrect tRNA pairs with an mRNA codon at the aminoacyl site of the ribosome, adenosines 1492 and 1493 are excluded from the interaction and retract, signaling the ribosome to reject the aminoacylated tRNA::Elongation Factor Thermo-Unstable complex. [24] However, when gentamicin binds at helix 44 of the 16S rRNA, it forces the adenosines to maintain the position they take when there is a correct, or cognate, match between aa-tRNA and mRNA. [25] This leads to the acceptance of incorrect aa-tRNAs, causing the ribosome to synthesize proteins with wrong amino acids placed throughout (roughly every 1 in 500). [26] The non-functional, mistranslated proteins misfold and aggregate, eventually leading to death of the bacterium. A secondary mechanism has been proposed based on crystal structures of gentamicin in a secondary binding site at helix 69 of the 23S rRNA, which interacts with helix 44 and proteins that recognize stop codons. At this secondary site, gentamicin is believed to preclude interactions of the ribosome with ribosome recycling factors, causing the two subunits of the ribosome to stay complexed even after translation completes. This creates a pool of inactive ribosomes that can no longer re-initiate and translate new proteins. [27]

Chemistry

Structure

FixedC1primeStereospecific Gentamicin IUPAC Numbered copy.png

Since gentamicin is derived from the species Micromonospora , the backbone for this antibiotic is the aminocyclitol 2-deoxystreptamine. [28] [29] This six carbon ring is substituted at the carbon positions 4 and 6 by the amino sugar molecules cyclic purpurosamine and garosamine, respectively. [30] [28] The gentamicin complex, is differentiated into five major components (C1, C1a, C2, C2a, C2b) and multiple minor components by substitution at the 6' carbon of the purpurosamine unit indicated in the image to the right by R1 and R2. [30] [28] [31] [32] The R1 and R2 can have the follow substitutions for some of the species in the gentamicin complex. [30] [33] [29]

Major component
C complexR1R2
C1 Methyl group Methyl group
C1a Hydrogen Hydrogen
C2 Hydrogen Methyl group
C2a Hydrogen Methyl group
C2b Methyl group Hydrogen

Components

Gentamicin is composed of a number of related gentamicin components and fractions which have varying degrees of antimicrobial potency. [34] The main components of gentamicin include members of the gentamicin C complex: gentamicin C1, gentamicin C1a, and gentamicin C2 which compose approximately 80% of gentamicin and have been found to have the highest antibacterial activity. Gentamicin A, B, X, and a few others make up the remaining 20% of gentamicin and have lower antibiotic activity than the gentamicin C complex. [32] The exact composition of a given sample or lot of gentamicin is not well defined, and the level of gentamicin C components or other components in gentamicin may differ from lot-to-lot depending on the gentamicin manufacturer or manufacturing process. Because of this lot-to-lot variability, it can be difficult to study various properties of gentamicin including pharmacokinetics and microorganism susceptibility if there is an unknown combination of chemically related but different compounds. [35]

Biosynthesis

The complete biosynthesis of gentamicin is not entirely elucidated. The genes controlling the biosynthesis of gentamicin are of particular interest due to the difficulty in obtaining the antibiotic after production. [32] [31] [33] [36] [37] Since gentamicin is collected at the cell surface and the cell surface must be perforated somehow to obtain the antibiotic. [32] [31] [33] [36] [37] Many propose the amount of gentamicin collected after production could increase if the genes are identified and re-directed to secrete the antibiotic instead of collecting gentamicin at the cell surface. [32] [31] [33] [36] [37] Literature also agrees with the gentamicin biosynthesis pathway starting with D-Glucose-6-phosphate being dephopsphorylated, transaminated, dehydrogenated and finally glycosylated with D-glucosamine to generate paromamine inside Micromonospora echinospora. [30] The addition of D-xylose leads to the first intermediate of the gentamicin C complex pathway, gentamicin A2. [30] [38] Gentamicin A2 is C-methylated and epimerized into gentamicin X2, the first branch point of this biosynthesis pathway [38]

When X2 is acted on by the cobalamin-dependent radical S-adenosyl-L-methionine enzyme GenK, the carbon position 6' is methylated to form the pharmacologically active intermediate G418 [39] [38] [30] [40] G418 then undergoes dehydrogenation and amination at the C6' position by the dehydrogenase gene, GenQ, to generate the pharmacologically active JI-20B, although another intermediate, 6'-dehydro-6'oxo-G418 (6'DOG) is proposed to be in-between this step and for which the gene GenB1 is proposed as the aminating gene. [30] [41] JI-20B is dehydroxylated and epimerized to first component of the gentamicin C complex, gentamicin C2a which then undergoes an epimerization by GenB2 and then a N-methylation by an unconfirmed gene to form the final product in this branch point, gentamicin C1. [38] [41] [30] [42]

When X2 bypasses GenK and is directly dehydrogenated and aminated by the GenQ enzyme, the other pharmacologically relevant intermediate JI-20A is formed. [30] [41] Although, there has been identification of an intermediate for this step, 6'-dehydro-6'-oxo-gentamicin X2 (6'-DOX), for which the enzyme GenB1 is purposed as the aminating enzyme. [41] JI-20A is then dehydroxylated into the first component of the gentamicin C complex for this branch, gentamicin C1a via a catalytic reaction with GenB4. [42] C1a then undergoes an N-methylation by an unconfirmed enzyme to form the final component, gentamicin C2b. [41] [38] [30] [42]

Fermentation

Gentamicin is only synthesized via submerged fermentation and inorganic sources of nutrients have been found to reduce production. [30] Traditional fermentation used yeast beef broth, [31] but there has been research into optimizing the growth medium for producing gentamicin C complex due to the C complex currently being the only pharmaceutically relevant component. [30] The main components of the growth medium are carbon sources, mainly sugars, but several studies found increased gentamicin production by adding vegetable and fish oils and decreased gentamicin production with the addition of glucose, xylose and several carboxylic acids. [30] Tryptone and various forms of yeast and yeast derivatives are traditionally used as the nitrogen source in the growth medium, but several amino acids, soybean meal, corn steep liquor, ammonium sulfate, and ammonium chloride have proven to be beneficial additives. [30] [33] Phosphate ions, metal ions (cobalt and a few others at low concentration), various vitamins (mostly B vitamins), purine and pyrimidine bases are also supplemented into the growth medium to increase gentamicin production, but the margin of increase is dependent on the species of Micromonospora and the other components in the growth medium. [30] [36] With all of these aforementioned additives, pH and aeration are key determining factors for the amount of gentamicin produced. [30] [33] A range of pH from 6.8 to 7.5 is used for gentamicin biosynthesis and the aeration is determined by independent experimentation reliant on type of growth medium and species of Micromonospora. [30] [33]

History

Gentamicin for injection Gentamicin for injection.jpg
Gentamicin for injection

Gentamicin is produced by the fermentation of Micromonospora purpurea . It was discovered in 1963 by Weinstein, Wagman et al. at Schering Corporation in Bloomfield, N.J. while working with source material (soil samples) provided by Rico Woyciesjes. [8] When M. purpurea grows in culture it is a vivid purple colour similar to the colour of the dye Gentian Violet and hence this was why Gentamicin took then name it did. Subsequently, it was purified and the structures of its three components were determined by Cooper, et al., also at the Schering Corporation. It was initially used as a topical treatment for burns at burn units in Atlanta and San Antonio and was introduced into IV usage in 1971. It remains a mainstay for use in sepsis.[ citation needed ]

It is synthesized by Micromonospora , a genus of Gram-positive bacteria widely present in the environment (water and soil). According to the American Medical Association Committee on Generic Names, antibiotics not produced by Streptomyces should not use y in the ending of the name, and to highlight their specific biological origins, gentamicin and other related antibiotics produced by this genus (verdamicin, mutamicin, sisomicin, netilmicin, and retymicin) have their spellings ending in ~micin and not in ~mycin. [43]

Research

Gentamicin is also used in molecular biology research as an antibacterial agent in tissue and cell culture, to prevent contamination of sterile cultures. Gentamicin is one of the few heat-stable antibiotics that remain active even after autoclaving, which makes it particularly useful in the preparation of some microbiological growth media.[ citation needed ]

Related Research Articles

<i>Staphylococcus aureus</i> Species of Gram-positive bacterium

Staphylococcus aureus is a Gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It is often positive for catalase and nitrate reduction and is a facultative anaerobe that can grow without the need for oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning. Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA), is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved.

<span class="mw-page-title-main">Vancomycin</span> Antibiotic medication

Vancomycin is a glycopeptide antibiotic medication used to treat a number of bacterial infections. It is used intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. Blood levels may be measured to determine the correct dose. Vancomycin is also taken orally as a treatment for severe Clostridium difficile colitis. When taken orally it is poorly absorbed.

<span class="mw-page-title-main">Streptomycin</span> Aminoglycoside antibiotic

Streptomycin is an antibiotic medication used to treat a number of bacterial infections, including tuberculosis, Mycobacterium avium complex, endocarditis, brucellosis, Burkholderia infection, plague, tularemia, and rat bite fever. For active tuberculosis it is often given together with isoniazid, rifampicin, and pyrazinamide. It is administered by injection into a vein or muscle.

<span class="mw-page-title-main">Neomycin</span> Type of antibiotic

Neomycin is an aminoglycoside antibiotic that displays bactericidal activity against gram-negative aerobic bacilli and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against gram-positive bacilli and anaerobic gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the aminoglycoside class of antibiotics that contain two or more amino sugars connected by glycosidic bonds.

<span class="mw-page-title-main">Aminoglycoside</span> Antibacterial drug

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside (sugar). The term can also refer more generally to any organic molecule that contains amino sugar substructures. Aminoglycoside antibiotics display bactericidal activity against Gram-negative aerobes and some anaerobic bacilli where resistance has not yet arisen but generally not against Gram-positive and anaerobic Gram-negative bacteria.

Ototoxicity is the property of being toxic to the ear (oto-), specifically the cochlea or auditory nerve and sometimes the vestibular system, for example, as a side effect of a drug. The effects of ototoxicity can be reversible and temporary, or irreversible and permanent. It has been recognized since the 19th century. There are many well-known ototoxic drugs used in clinical situations, and they are prescribed, despite the risk of hearing disorders, for very serious health conditions. Ototoxic drugs include antibiotics, loop diuretics, and platinum-based chemotherapy agents. A number of nonsteroidal anti-inflammatory drugs (NSAIDS) have also been shown to be ototoxic. This can result in sensorineural hearing loss, dysequilibrium, or both. Some environmental and occupational chemicals have also been shown to affect the auditory system and interact with noise.

Nephrotoxicity is toxicity in the kidneys. It is a poisonous effect of some substances, both toxic chemicals and medications, on kidney function. There are various forms, and some drugs may affect kidney function in more than one way. Nephrotoxins are substances displaying nephrotoxicity.

<span class="mw-page-title-main">Paromomycin</span> Chemical compound

Paromomycin is an antimicrobial used to treat a number of parasitic infections including amebiasis, giardiasis, leishmaniasis, and tapeworm infection. It is a first-line treatment for amebiasis or giardiasis during pregnancy. Otherwise, it is generally a second line treatment option. It is taken by mouth, applied to the skin, or by injection into a muscle.

<span class="mw-page-title-main">Kanamycin A</span> Antibiotic

Kanamycin A, often referred to simply as kanamycin, is an antibiotic used to treat severe bacterial infections and tuberculosis. It is not a first line treatment. It is used by mouth, injection into a vein, or injection into a muscle. Kanamycin is recommended for short-term use only, usually from 7 to 10 days. As with most antibiotics, it is ineffective in viral infections.

<i>Pseudomonas aeruginosa</i> Species of bacterium

Pseudomonas aeruginosa is a common encapsulated, Gram-negative, aerobic–facultatively anaerobic, rod-shaped bacterium that can cause disease in plants and animals, including humans. A species of considerable medical importance, P. aeruginosa is a multidrug resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious illnesses – hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes. P. aeruginosa is able to selectively inhibit various antibiotics from penetrating its outer membrane - and has high resistance to several antibiotics, according to the World Health Organization P. aeruginosa poses one of the greatest threats to humans in terms of antibiotic resistance.

<span class="mw-page-title-main">Tobramycin</span> Chemical compound

Tobramycin is an aminoglycoside antibiotic derived from Streptomyces tenebrarius that is used to treat various types of bacterial infections, particularly Gram-negative infections. It is especially effective against species of Pseudomonas.

<span class="mw-page-title-main">Amikacin</span> Antibiotic medication

Amikacin is an antibiotic medication used for a number of bacterial infections. This includes joint infections, intra-abdominal infections, meningitis, pneumonia, sepsis, and urinary tract infections. It is also used for the treatment of multidrug-resistant tuberculosis. It is used by injection into a vein using an IV or into a muscle.

<span class="mw-page-title-main">Spectinomycin</span> Antibiotic

Spectinomycin, sold under the tradename Trobicin among others, is an antibiotic useful for the treatment of gonorrhea infections. It is given by injection into a muscle.

<span class="mw-page-title-main">Netilmicin</span> Chemical compound

Netilmicin (1-N-ethylsisomicin) is a semisynthetic aminoglycoside antibiotic, and a derivative of sisomicin, produced by Micromonospora inyoensis. Aminoglycoside antibiotics have the ability to kill a wide variety of bacteria. Netilmicin is not absorbed from the gut and is therefore only given by injection or infusion. It is only used in the treatment of serious infections particularly those resistant to gentamicin.

<span class="mw-page-title-main">Sisomicin</span> Chemical compound

Sisomicin, is an aminoglycoside antibiotic, isolated from the fermentation broth of Micromonospora inositola. It is a newer broad-spectrum aminoglycoside most structurally related to gentamicin.

<span class="mw-page-title-main">Dihydrostreptomycin</span> Chemical compound

Dihydrostreptomycin is a derivative of streptomycin that has a bactericidal properties. It is a semisynthetic aminoglycoside antibiotic used in the treatment of tuberculosis.

<span class="mw-page-title-main">Protein synthesis inhibitor</span> Inhibitors of translation

A protein synthesis inhibitor is a compound that stops or slows the growth or proliferation of cells by disrupting the processes that lead directly to the generation of new proteins.

<span class="mw-page-title-main">Arbekacin</span> Antibiotic

Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.

16S rRNA (guanine1405-N7)-methyltransferase (EC 2.1.1.179, methyltransferase Sgm, m7G1405 Mtase, Sgm Mtase, Sgm, sisomicin-gentamicin methyltransferase, sisomicin-gentamicin methylase, GrmA, RmtB, RmtC, ArmA) is an enzyme with systematic name S-adenosyl-L-methionine:16S rRNA (guanine1405-N7)-methyltransferase. This enzyme catalyses the following chemical reaction

<span class="mw-page-title-main">Ototoxic medication</span>

Ototoxicity is defined as the toxic effect on the functioning of the inner ear, which may lead to temporary or permanent hearing loss (cochleotoxic) and balancing problems (vestibulotoxic). Drugs or pharmaceutical agents inducing ototoxicity are regarded as ototoxic medications.

References

  1. ↑ "Gentamicin Use During Pregnancy". Drugs.com. 28 February 2019. Retrieved 11 February 2020.
  2. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  3. ↑ "Active substance: gentamicin (systemic use)" (PDF). List of nationally authorised medicinal products. European Medicines Agency. 26 November 2020.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Gentamicin sulfate". The American Society of Health-System Pharmacists. Archived from the original on 16 August 2015. Retrieved 15 August 2015.
  5. ↑ Bartlett J (2013). Clinical Ocular Pharmacology (s ed.). Elsevier. p. 214. ISBN   9781483193915. Archived from the original on 22 December 2015.
  6. ↑ Moulds R, Jeyasingham M (October 2010). "Gentamicin: a great way to start". Australian Prescriber. 33 (5): 134–135. doi: 10.18773/austprescr.2010.062 .
  7. ↑ "Gentamicin use while breastfeeding". Archived from the original on 6 September 2015. Retrieved 15 August 2015.
  8. 1 2 Weinstein MJ, Luedemann GM, Oden EM, Wagman GH, Rosselet JP, Marquez JA, et al. (July 1963). "Gentamicin, a new antibiotic complex from Micromonospora". Journal of Medicinal Chemistry. 6 (4): 463–464. doi:10.1021/jm00340a034. PMID   14184912.
  9. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 507. ISBN   9783527607495.
  10. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  11. ↑ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl: 10665/312266 . ISBN   9789241515528. License: CC BY-NC-SA 3.0 IGO.
  12. ↑ Burchum J (2014). Lehne's pharmacology for nursing care. Elsevier Health Sciences. p. 1051. ISBN   9780323340267. Archived from the original on 11 March 2016.
  13. 1 2 3 4 5 6 7 8 9 "Gentamicin" (PDF). Baxter Corporation. Archived from the original (PDF) on 4 March 2016. Retrieved 2 November 2015.
  14. 1 2 3 4 5 "Gentamicin Injection USP" (PDF). Product Monograph. Sandoz Canada Inc. Archived from the original (PDF) on 12 April 2015. Retrieved 2 November 2015.
  15. ↑ Hathorn E, Dhasmana D, Duley L, Ross JD (September 2014). "The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review". Systematic Reviews. 3: 104. doi: 10.1186/2046-4053-3-104 . PMC   4188483 . PMID   25239090.
  16. ↑ Goljan EF (2011). Rapid Review Pathology (3rd ed.). Philadelphia, Pennsylvania: Elsevier. p. 241. ISBN   978-0-323-08438-3.
  17. ↑ "Gentamicin spectrum of bacterial susceptibility and Resistance" (PDF). TOKU-E. Archived from the original (PDF) on 20 February 2015. Retrieved 15 May 2012.
  18. ↑ Sato Y (February 1997). "Pharmacokinetics of antibiotics in neonates". Acta Paediatrica Japonica. 39 (1): 124–131. doi:10.1111/j.1442-200X.1997.tb03569.x. PMID   9124044. S2CID   23564581.
  19. ↑ Santos JI, Swensen P, Glasgow LA (July 1981). "Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations". Pediatrics. 68 (1): 50–54. doi:10.1542/peds.68.1.50. PMID   7243509. S2CID   36001577.
  20. 1 2 3 4 Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ (January 2011). "New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view". Kidney International. 79 (1): 33–45. doi: 10.1038/ki.2010.337 . PMID   20861826.
  21. ↑ East JE, Foweraker JE, Murgatroyd FD (May 2005). "Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin". Heart. 91 (5): e32. doi:10.1136/hrt.2003.028308. PMC   1768868 . PMID   15831617.
  22. 1 2 Selimoglu E (1 January 2007). "Aminoglycoside-induced ototoxicity". Current Pharmaceutical Design. 13 (1): 119–126. doi:10.2174/138161207779313731. PMID   17266591.
  23. ↑ "DrugBank-Gentamicin". Archived from the original on 4 October 2013.
  24. ↑ Dao EH, Poitevin F, Sierra RG, Gati C, Rao Y, Ciftci HI, et al. (December 2018). "Structure of the 30S ribosomal decoding complex at ambient temperature". RNA. 24 (12): 1667–1676. doi:10.1261/rna.067660.118. PMC   6239188 . PMID   30139800.
  25. ↑ Wilson DN (January 2014). "Ribosome-targeting antibiotics and mechanisms of bacterial resistance". Nature Reviews. Microbiology. 12 (1): 35–48. doi:10.1038/nrmicro3155. PMID   24336183. S2CID   9264620.
  26. ↑ Garrett R, Douthwaite S, Liljas A, Matheson A, Moore P, Harry N (2000). The Ribosome. ASM Press. pp. 419–429. ISBN   978-1-55581-184-6.
  27. ↑ Borovinskaya MA, Pai RD, Zhang W, Schuwirth BS, Holton JM, Hirokawa G, et al. (August 2007). "Structural basis for aminoglycoside inhibition of bacterial ribosome recycling". Nature Structural & Molecular Biology. 14 (8): 727–732. doi:10.1038/nsmb1271. PMID   17660832. S2CID   31576287.
  28. 1 2 3 Yu Y, Zhang Q, Deng Z (18 May 2017). "Parallel pathways in the biosynthesis of aminoglycoside antibiotics". F1000Research. 6: 723. doi: 10.12688/f1000research.11104.1 . PMC   5461906 . PMID   28620453.
  29. 1 2 Dewick PM (2009). Medicinal natural products : a biosynthetic approach (3rd ed.). Chichester, West Sussex, United Kingdom. pp. 738–750. ISBN   978-0-470-74167-2.{{cite book}}: CS1 maint: location missing publisher (link)
  30. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Kumar CG, Himabindu M, Jetty A (January 2008). "Microbial biosynthesis and applications of gentamicin: a critical appraisal". Critical Reviews in Biotechnology. 28 (3): 173–212. doi:10.1080/07388550802262197. PMID   18937107. S2CID   83784820.
  31. 1 2 3 4 5 Weinstein MJ, Wagman GH, Oden EM, Marquez JA (September 1967). "Biological activity of the antibiotic components of the gentamicin complex". Journal of Bacteriology. 94 (3): 789–790. doi:10.1128/jb.94.3.789-790.1967. PMC   251956 . PMID   4962848.
  32. 1 2 3 4 5 Vydrin AF, Shikhaleev IV, Makhortov VL, Shcherenko NN, Kolchanova NV (2003). "Component Composition of Gentamicin Sulfate Preparations". Pharmaceutical Chemistry Journal. 37 (8): 448–450. doi:10.1023/a:1027372416983. S2CID   43731658.
  33. 1 2 3 4 5 6 7 Daniels PJ, Luce C, Nagabhushan TL (January 1975). "The gentamicin antibiotics. 6. Gentamicin C2b, an aminoglycoside antibiotic produced by Micromonospora purpurea mutant JI-33". The Journal of Antibiotics. 28 (1): 35–41. doi: 10.7164/antibiotics.28.35 . PMID   1092638.
  34. ↑ Weinstein MJ, Wagman GH, Oden EM, Marquez JA (September 1967). "Biological activity of the antibiotic components of the gentamicin complex". Journal of Bacteriology. 94 (3): 789–790. doi:10.1128/JB.94.3.789-790.1967. PMC   251956 . PMID   4962848.
  35. ↑ Isoherranen N, Lavy E, Soback S (June 2000). "Pharmacokinetics of gentamicin C(1), C(1a), and C(2) in beagles after a single intravenous dose". Antimicrobial Agents and Chemotherapy. 44 (6): 1443–1447. doi:10.1128/aac.44.6.1443-1447.2000. PMC   89894 . PMID   10817690.
  36. 1 2 3 4 Wagman GH, Testa RT, Marquez JA (November 1970). "Antibiotic 6640. II. Fermentation, isolation, and properties". The Journal of Antibiotics. 23 (11): 555–558. doi: 10.7164/antibiotics.23.555 . PMID   5487130.
  37. 1 2 3 Chu J, Zhang S, Zhuang Y, Chen J, Li Y (December 2002). "Factors affecting the biosynthesis and secretion of gentamicin". Process Biochemistry. 38 (5): 815–820. doi:10.1016/S0032-9592(02)00230-3.
  38. 1 2 3 4 5 Testa RT, Tilley BC (February 1976). "Biotransformation, a new approach to aminoglycoside biosynthesis: II. Gentamicin". The Journal of Antibiotics. 29 (2): 140–146. doi: 10.7164/antibiotics.29.140 . PMID   931800.
  39. ↑ Kim HJ, McCarty RM, Ogasawara Y, Liu YN, Mansoorabadi SO, LeVieux J, Liu HW (June 2013). "GenK-catalyzed C-6' methylation in the biosynthesis of gentamicin: isolation and characterization of a cobalamin-dependent radical SAM enzyme". Journal of the American Chemical Society. 135 (22): 8093–8096. doi:10.1021/ja312641f. PMC   3796153 . PMID   23679096.
  40. ↑ Hong W, Yan L (2012). "Identification of gntK, a gene required for the methylation of purpurosamine C-6' in gentamicin biosynthesis". The Journal of General and Applied Microbiology. 58 (5): 349–356. doi: 10.2323/jgam.58.349 . PMID   23149679.
  41. 1 2 3 4 5 Guo J, Huang F, Huang C, Duan X, Jian X, Leeper F, et al. (May 2014). "Specificity and promiscuity at the branch point in gentamicin biosynthesis". Chemistry & Biology. 21 (5): 608–618. doi:10.1016/j.chembiol.2014.03.005. PMC   4039129 . PMID   24746560.
  42. 1 2 3 Chen X, Zhang H, Zhou S, Bi M, Qi S, Gao H, et al. (March 2020). "The bifunctional enzyme, GenB4, catalyzes the last step of gentamicin 3',4'-di-deoxygenation via reduction and transamination activities". Microbial Cell Factories. 19 (1): 62. doi: 10.1186/s12934-020-01317-0 . PMC   7063804 . PMID   32156271.
  43. ↑ Waisbren BA (1 April 1969). "Experiences with the new antibiotic gentamicin". The Journal of Infectious Diseases. 119 (4): 518–536. doi:10.1093/infdis/119.4-5.528. PMID   4306977.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.